K-Stat 250 Tablet contains Ethamsylate 250 mg, a hemostatic agent used to reduce bleeding by promoting capillary endothelial stability and enhancing platelet adhesion. It is commonly indicated for the prevention and treatment of hemorrhages in various clinical settings, including menorrhagia, postoperative bleeding, and bleeding associated with capillary fragility. Ethamsylate acts by improving platelet function and restoring capillary resistance, thereby reducing bleeding time without affecting coagulation parameters. K-Stat 250 is particularly useful in controlling bleeding in surgical procedures, dental extractions, and obstetric hemorrhages. The tablet is administered orally, with dosage tailored according to the severity of bleeding and patient response. It is generally well tolerated, with adverse effects being rare but may include gastrointestinal disturbances such as nausea or mild allergic reactions. Caution is advised in patients with known hypersensitivity to Ethamsylate or any tablet excipients. K-Stat 250 should be used under medical supervision, especially in individuals with coagulation disorders or those receiving anticoagulant therapy. Regular monitoring is recommended to assess therapeutic efficacy and detect any potential side effects. This medication provides an effective option for managing bleeding episodes, contributing to improved patient outcomes in hemorrhagic conditions.